|
| Exchange Received Time 29/09/2018 13:59:45 Exchange Disseminated Time 29/09/2018 13:59:51 Time Taken 00:00:06 | With reference to captioned subject, the Company had informed you vide its letter dated September 20, 2018 that the Board of Directors of the Company at its Meeting held on September 20, 2018, inter alia has approved the Scheme of Amalgamation of Gufic Lifesciences Private Limited with the Company and their respective shareholders and creditors, subject to the approval of the shareholders and regulatory authorities.
This is to further inform you that there was a typographical error in 2nd paragraph of clause (v) on page no. 3 of Annexure 'A', whereby the Company had erroneously and inadvertently mentioned the number of shares to be exchanged against the outstanding unsecured loan of the Transferor Company as '58,87,662 equity shares of Face Value of Re. 1/-' each instead of '59,03,835 equity shares of Face Value of Re. 1/- each'. |
|
|